trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7 Ubunyulu >98.0% (HPLC) Afatinib Dimaleate Intermediate

Inkcazelo emfutshane:

i-trans-4-Dimethylaminocrotonic Acid Hydrochloride

CAS: 848133-35-7

Ubunyulu: >98.0% (HPLC)

Imbonakalo: Mhlophe ukuya phantse kuMhlophe

Phakathi kwe-Afatinib Dimaleate (CAS: 850140-73-7)

Qhagamshelana: UGqr. Alvin Huang

Iselula/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

I-Ruifu Chemical Supply Intermediates ye-Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino)i-acetaldehyde I-Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
I-Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4 (1H)-enye CAS 162012-69-3
I-7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineI-CAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineI-CAS 314771-88-5

Iipropati zeMichiza:

Igama leMchiza	i-trans-4-Dimethylaminocrotonic Acid Hydrochloride
Izithethantonye	i-trans 4-Dimethylaminocrotonic Acid HCl;(E) -4-(Dimethylamino) -2-Butenoic Acid Hydrochloride;(E) -4-Dimethylaminocrotonic Acid Hydrochloride;(2E) -4-(Dimethylamino) kodwa-2-Enoic Acid Hydrochloride;Afatinib int-2
Inombolo yeCAS	848133-35-7
Ubume beStokhwe	Kwisitokhwe, isikali soRhwebo
Ifomula yeemolekyuli	I-C6H12ClNO2
Ubunzima beMolekyuli	165.62
Uvakalelo	Hygroscopic.Ukungenwa kukufuma
Indawo yokunyibilika	160.0 ukuba 164.0℃
Ukunyibilika	I-DMSO (Kancinci), iMethanol (Kancinci), Amanzi (Kancinci)
I-COA kunye ne-MSDS	Iyafumaneka
Imvelaphi	Shanghai, China
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Mhlophe ukuya Phantse uMhlophe
Ubunyulu / Indlela yokuHlalutya	>98.0% (HPLC)
Ubunyulu / Indlela yokuHlalutya	>98.0% (NMR)
Ukufuma (KF)	<0.50%
Intsalela kwi-Ignition	<0.20%
Ukungacoceki Okukodwa	<0.50%
Iintsimbi ezinzima (njenge Pb)	<20ppm
I-Infrared Spectrum	Iyahambelana neSakhiwo
I-1 H NMR Spectrum	Proton NMR Spectrum
Umgangatho woVavanyo	Umgangatho woShishino
Ukusetyenziswa	Umbindi weAfatinib, Afatinib Dimaleate

Ukupakishwa kunye noGcino:

Umqulu:Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma.

Ukuhambisa ngenqanawe:Zisa kwihlabathi liphela ngomoya, ngeFedEx / DHL Express.Ukubonelela ngokukhawuleza nangokuthembekileyo.

Ubunyulu beChromatographic:

Isixhobo: I-Agilent 1200 HPLC HPLC chromatograph, i-DAD detector.
Uluhlu: Agilent XDB-C18,250 * 4.6mm, 5μm
Isigaba seselula: B: 1.95g sodium octane sulfonate + 8ml phosphoric acid + 5ml triethylamine + 500ml amanzi
C: i-acetonitrile
Ukulungiswa kwesigaba esixubileyo se-mobile: thabatha isisombululo se-400ml B kunye ne-100ml ye-acetonitrile, xuba ngokucokisekileyo kwaye ulungelelanise, kwaye upompe ulwelo kwisigaba esinye.
Isantya sokuhamba: 0.5ml/min54bar
Ubushushu bekholamu: 25℃
Ubude bobude: 210nm
Isisombululo sesampuli: isigaba seselula sisetyenziswe njenge-solvent, isampuli eqinile: 0.0040g / 2ml, ubungakanani besampula 2.0μl.

Izinto eziluncedo:

FAQ:

Isicelo:

I-trans-4-Dimethylaminocrotonic Acid Hydrochloride (CAS: 848133-35-7) i-reagent esetyenziselwa ukulungiswa kwe-tyrosine kinase inhibiting agents antitumor.I-trans-4-Dimethylaminocrotonic Acid Hydrochloride ingasetyenziselwa njenge-intermediate ye-Afatinib (CAS: 439081-18-2), i-Afatinib Dimaleate (CAS: 850140-73-7), i-Neratinib (CAS: 698387-09-6).I-Afatinib lichiza elivunyiweyo kunyango lwe-non-small cell lung carcinoma (NSCLC), ephuhliswe ngu-Boehringer Ingelheim.Isebenza njenge-angiokinase inhibitor.NjengeLapatinib kunye neNeratinib, i-Afatinib yi-tyrosine kinase inhibitor (TKI) ekwathintela ngokungenakuguquleka kwi-epidermal growth factor receptor 2 (Her2) kunye ne-epidermal growth factor receptor (EGFR) kinases.I-Afatinib ayisebenzi kuphela kwi-EGFRutshintsho olujoliswe kwisizukulwana sokuqala se-TKIs likeerlotinib okanye i-gefitinib, kodwa nakwabo bangenaluvelwano kolu nyango luqhelekileyo.Ngenxa yomsebenzi wayo owongezelelweyo ngokuchasene ne-Her2, iphandwa umhlaza wamabele kunye neminye imihlaza eqhutywa yi-EGFR kunye ne-Her2.I-Neratinib ephuhliswe yinkampani yase-US Wyeth yi-epidermal growth factor receptor (EGFR) inhibitor engaguqulekiyo.Iyindawo ekujoliswe kuyo emininzi ye-molecule encinci ye-tyrosine kinase inhibitors ukuya kwi-HER 2 kunye ne-HER1 emva kweLapatinib, kwaye i-ErbB engenakuguquleka ye-receptor tyrosine kinase inhibitor.I-Neratinib inokunqanda ngokukhethekileyo i-HER-1 kunye ne-HER-2 yentsapho ye-EGFR (IC50 yayingu-92 nmol / L kunye ne-59 nmol / L, ngokulandelanayo).Uphando lweklinikhi lubonise ukuba iNeratinib yenza isiphumo esibalulekileyo sonyango kumhlaza wemiphunga weseli ongengomncinci, umhlaza wekoloni, kunye nomhlaza wamabele.Ulingo lwe-phaseⅡclinical lubonise ukuba iNeratinib ibonise ukusebenza kakuhle kunye nokunyamezelana kwi-HER-2 izigulane ezinesifo somhlaza webele ophezulu oye wafunyanwa okanye akafumani unyango lweTrastuzumab.Isigaba Ⅲ solingo lwezonyango lomhlaza wamabele lwagqitywa ngoSeptemba wama-2014.